Investors & Media
What’s new.


Press releases
Press releases.
January 31st 2025
Immutep Quarterly Activities Report Q2 FY25
January 22nd 2025
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
January 6th 2025
Patient Enrolment Completed for INSIGHT-003
Investor updates
Analyst reports
Analyst reports.
January 24th 2025
Canaccord Genuity - TACTI-003 Cohort B musings, anticipated upcoming news flow; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)
December 17th 2024